THIO sequenced with Libtayo extended overall survival in those with non–small cell lung cancer who progressed on two or more ...

Moments after Regeneron CEO Len Schleifer scolded analysts for asking too many questions about the disappointing sales of eye ...

“At the first prespecified interim analysis, Libtayo achieved a remarkably high bar in improving disease-free survival in high-risk cutaneous squamous cell carcinoma. With no currently approved ...

Adjuvant cemiplimab prolonged DFS compared with placebo for certain patients with cutaneous squamous cell carcinoma, according to the agent’s manufacturer. Cemiplimab (Libtayo, Regeneron ...

However, Regeneron recently announced that its PD-1 inhibitor LIBTAYO had met its primary endpoint among patients with high risk cutaneous squamous cell carcinoma (CSCC). This positive news in ...

The study enrolled women with squamous cell carcinoma and adenocarcinoma forms of cervical cancer, and the death rate in those subgroups was reduced by 27% and 44%, respectively, with Libtayo.

Regeneron Pharmaceuticals has shared positive results from a late-stage trial of Libtayo (cemiplimab) in patients with high-risk cutaneous squamous cell carcinoma (CSCC) after surgery. The phase 3 ...

Regeneron's Q4 earnings report shows revenue growth, stable EYLEA sales, dividend announcement, and impressive growth for ...

Cemiplimab significantly reduced the risk of recurrence or death in patients with high-risk cutaneous squamous cell carcinoma (CSCC) post-surgery. Adjuvant treatment with cemiplimab (Libtayo ...

which evaluated the efficacy of the immunotherapy drug Libtayo (cemiplimab) in patients with high-risk cutaneous squamous cell carcinoma (CSCC) following surgery. The trial met its primary endpoint, ...

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...